Active immunotherapy in advanced melanoma patients
Clinical protocolThe vaccine is composed by autologous DCs electroporated with mRNA encoding CD40L, CD70, caTLR4 and one tumorantigen (gp100, Tyrosinase, Mage-C2 or Mage-A3).
Protocol Steps:
-
Electroporation
Electroporation of autologous DCs electroporated with mRNA encoding CD40L, CD70, caTLR4 and one tumorantigen (gp100, Tyrosinase, Mage-C2 or Mage-A3) to produce the vaccine
-
Vaccination of patients
Advanced melanoma patients are vaccinated with the DC vaccine.

- biomaterial type
- dendritic cell,
- melanoma antigen MAGE-3,
- CD70,
- gp100 antigen,
- CD40 ligand,
- Toll like receptor 4,
- tyrosinase,
- messenger RNA
created over 16 years ago
(2 March 2009)
last modified over 14 years ago
(28 September 2011)
[ RDF ]
[ RelFinder
]